ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Eyetech Pharmaceuticals (MM)

Eyetech Pharmaceuticals (MM) (EYET)

0.00
0.00
(0.00%)
Closed February 04 3:00PM
0.00
0.00
(0.00%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
-
Bid
-
Ask
-
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
-
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

EYET Latest News

OSI Pharmaceuticals and Eyetech Pharmaceuticals Confirm November 14th Closing

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Eyetech Pharmaceuticals, Inc. (NASDAQ: EYET) today announced that the closing of the OSI acquisition of Eyetech will occur on Monday, November...

Eyetech Provides Update on Status of Pending Acquisition by OSI Pharmaceuticals

Stockholders Overwhelmingly Approve Merger NEW YORK, Nov. 10 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET) provided an update today on the status of its pending...

Eyetech Reports Third Quarter 2005 Financial Results

Company achieves operating profitability, excluding certain charges, based on total revenue of $67.4 million and net product revenue of $55.5 million NEW YORK, Oct. 31 /PRNewswire-FirstCall/...

Eyetech Announces Enrollment of the First Patient in a Phase 3 Clinical Trial of Macugen(R) (pegaptanib sodium injection) in Dia

Phase 2 study of Macugen in diabetic macular edema (DME) published in the October issue of Ophthalmology NEW YORK, Oct. 17 /PRNewswire-FirstCall/ .- Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET...

Recent Analyses Suggest That Treatment With Macugen(R) (pegaptanib sodium injection) May Provide Better Results for Patients Wit

Retrospective, subgroup analyses of the VISION study suggest that treatment of early disease with Macugen may further reduce the risk of vision loss associated with neovascular AMD compared to the...

Macugen(R) (pegaptanib sodium injection) Receives Positive Opinion for Treatment of Neovascular Age-Related Macular Degeneration

NEW YORK, Sept. 16 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee...

OSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger Agreement

Acquisition Projected to be Accretive and Generate Combined 2006 Revenues of Over $600 Million MELVILLE, N.Y. and NEW YORK, Aug. 21 /PRNewswire-FirstCall/ -- OSI Pharmaceuticals, Inc...

OSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger Agreement; Acquisition Projected to be Acc

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Eyetech Pharmaceuticals, Inc. (NASDAQ: EYET) today announced that they have entered into a definitive merger agreement whereby OSI has agreed...

Macugen(R) (pegaptanib sodium injection) Named Innovative Pharmaceutical Product Of The Year At The 2005 Pharmaceutical Achievem

Award recognizes Macugen's breakthrough technology as the first anti- angiogenic treatment approved in ophthalmology and the first aptamer therapy approved by the FDA NEW YORK, Aug. 9...

Eyetech Reports Second Quarter 2005 Financial Results

Eyetech Reports Second Quarter 2005 Financial Results - Gross Product Revenue for Macugen(R) (pegaptanib sodium injection) increased to $50 million in the second quarter from $25 million in the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

EYET - Frequently Asked Questions (FAQ)

What is the current Eyetech share price?
The current share price of Eyetech is US$ 0.00
What is the 1 year trading range for Eyetech share price?
Eyetech has traded in the range of US$ 0.00 to US$ 0.00 during the past year

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
IVVDInvivyd Inc
US$ 1.055
(194.94%)
431.26M
HCWBHCW Biologics Inc
US$ 0.6265
(125.20%)
320.82M
UOKAMDJM Ltd
US$ 0.2293
(76.38%)
326.81M
GHRSGH Research PLC
US$ 17.9991
(69.80%)
9.71M
SOPASociety Pass Inc
US$ 2.43
(59.87%)
106.29M
CYNCYNGN Inc
US$ 0.1169
(-56.70%)
75.52M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.1943
(-54.61%)
327.95M
VIRXViracta Therapeutics Inc
US$ 0.0741
(-51.09%)
9.37M
BOWNUBowen Acquisition Corporation
US$ 3.39
(-49.55%)
17.28k
PITAHeramba Electric PLC
US$ 0.503
(-44.11%)
1.37M
IVVDInvivyd Inc
US$ 1.055
(194.94%)
431.26M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0462
(27.98%)
400.25M
NVDANVIDIA Corporation
US$ 116.66
(-2.84%)
333.74M
UOKAMDJM Ltd
US$ 0.2293
(76.38%)
326.81M
HCWBHCW Biologics Inc
US$ 0.6265
(125.20%)
320.82M

Discussion

View Full Feed
GrandAdmiralThrawn GrandAdmiralThrawn 5 minutes ago
I’m ready for today, let’s do this.
CLHI
WojD40 WojD40 10 minutes ago
You’re right that you can read it both ways and it means the same thing. It’s hard not to conclude the FDA application is being held back, or in some pre-submission state, in order to improve its chances. Be that manufacturing readiness, additional (specials?) data, or combo data. I hope the compan
NWBO
silattore silattore 14 minutes ago
Take your TDS and shove it up
XRPUSD
jog49 jog49 18 minutes ago
"Why is the fhfa wings not cut yet while cfpb alone was?"

Source of funding, I would say.
FNMA
The_Pro The_Pro 20 minutes ago
I would rather DewmBoom back versus Claytrader. Oldies will know him.

Great asset to this board.
BIEL
Researchfyi Researchfyi 22 minutes ago
So tell me. What has the company done for investors repetitiously?

I would tell you the answers, but I love to hear your carry the water for them replies.

Then again you know the answers from reading my posts.
LQMT
diamondguru-one diamondguru-one 22 minutes ago
New-WMI IPO offering to UQ escrow holders from the WMI-LT in Plan 6/DST/DCR.

The Possibility;
+$40/1.215 = $32.9 opening share price.
MC =+$40 Billion in hard assets

what's your thoughts on the share ratio ???

1 for 1
5 for 1
COOP
jog49 jog49 23 minutes ago
"We need to message ackman and tell him to shut the Fudge up about the warrants"

Thank you!
FNMA
DruidOracle55 DruidOracle55 23 minutes ago
1 million years
AXXA
benz280e benz280e 24 minutes ago
Fully reporting for 2025, on Melvins typical no communication procrastination calendar could very well mean March 15, 2026, more than an entire year from now, if ever at all...
GDVM
RickNagra RickNagra 25 minutes ago
Oh wow.  Incoming $$99 on deck.  Of oh wow amazing I will be a millionaire or maybe more hard to say in these times and the future is always going to be better for me.  DBMM is a great project and company to own and support the community and the team is very strong.  Best to win and own millions of
DBMM
nowwhat2 nowwhat2 25 minutes ago
https://investorshub.advfn.com/uimage/uploads/2025/2/4/vzkfptot_@_3_6m_11pm_bounce_then_whump.jpg




XRP 2.50 Baby.........HODL the bucking bronco !

https://investorshub.advfn.com/uimage/uploads/2025/2/4/ftxmxXRP_@_3_TRIO_930PM_100K_250_WHUMP.jpg
XRPUSD
pgsd pgsd 28 minutes ago
US biosimilar 'void' spells trouble as biologic patent expirations loom, IQVIA report says :
February 3, 2025

While 118 biologics are expected to lose patent protection in the US over the next decade, that $234 billion opportunity for biosimilar developers may not materialize b
NWBO
ham n slam ham n slam 30 minutes ago
people keep mentioning the high end piece of tail babs."..keep in mind 36 mil shares is one percent of the float...Emil holds 1 bil so 2.5 bil is out there on the garage sale table. alot of shares, imo..my gut tells me she can sell but why?hang on babs! you don't need a new wardrobe just yet!! chill
VPLM
oldmystic oldmystic 32 minutes ago
5.64 yes https://invst.ly/18qz13
https://media.stocktwits-cdn.com/api/3/media/1740042/medium.jpeg
AVXL
Investor082 Investor082 34 minutes ago
It’s funny how conversations always shift to manipulators or what retailers should do rather than what LP and the management team does for the shareholders. If they do not have non dilutive funds lined up after 4.5 years post data lock, and almost 3 years since TLD then LP has failed shareholders. N
NWBO
IceCold8 IceCold8 36 minutes ago
Some of us are filing complaints https://www.finra.org/investors/need-help/file-a-complaint I thought the market was bad under FJB, I'm thinking it's going to be even worse under this one,and I'm hoping I'm seriously wrong!
CGAC
doccjc doccjc 46 minutes ago
Great,,, I had sent a message on X,,, glad they fixed it,,
I can't get over the 80% reduction in tumor size and metastatic activity in 30 days !
RDGL
bbotcs bbotcs 49 minutes ago
mankind: Greenland 51st State, not Canada!
dinogreeves dinogreeves 49 minutes ago
Market is reversing into positive territory, reversing 80 point loss on Nasdaq, must be something cooking with these two super powers.
SMCI
bbotcs bbotcs 51 minutes ago
Gmenfan: Well the victims of the procedures will be able to sue her down the road.
nowwhat2 nowwhat2 51 minutes ago
When did he post that ?.......

https://investorshub.advfn.com/uimage/uploads/2025/2/4/dkzyqeth_@_3_duo_11pm_trump_said_buy_when.jpg


Answer - YUP !



Guy shouldn't even be ALLOWED to run around posting chit like that !

ETHUSD
bbotcs bbotcs 52 minutes ago
lj: I think Trump is looking at a U.S.-Canadian merger. Canada is a political Disneyland. This would be a good time for Quebec to go indy.
bbotcs bbotcs 53 minutes ago
lj: I think it was cancelled for this area. Film at 11.
mikepgator mikepgator 55 minutes ago
Nevermind, I emailed and got confirmation that it has been fixed.
RDGL

Your Recent History

Delayed Upgrade Clock